Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies

(2013) Nabil G. Seidah   CURRENT PHARMACEUTICAL DESIGN

An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo

(2013) Felix Schiele et al.   JOURNAL OF MOLECULAR BIOLOGY

Proprotein convertase subtilisin/kexin type 9 inhibition

(2012) David A. Marais et al.   CURRENT OPINION IN LIPIDOLOGY

Using Fragment-Based Technologies to Target Protein-Protein Interactions

(2012) Justin F. Bower et al.   CURRENT PHARMACEUTICAL DESIGN

Small-Molecule Inhibitors of Protein-Protein Interactions: How to Mimic a Protein Partner

(2012) David C. Fry   CURRENT PHARMACEUTICAL DESIGN

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

(2012) Yascara Grisel Luna Saavedra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain

(2012) Yingnan Zhang et al.   JOURNAL OF MOLECULAR BIOLOGY

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Phage Display-directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication

(2012) Belete A Desimmie et al.   MOLECULAR THERAPY

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

(2012) Nabil G. Seidah et al.   PLoS One

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor

(2011) Øystein L. Holla et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation

(2011) Yanqun Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification

(2011) K. Tveten et al.   HUMAN MOLECULAR GENETICS

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors

(2011) Øystein L. Holla et al.   JOURNAL OF LIPID RESEARCH

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

(2010) Yan G. Ni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

(2010) Mali Liu et al.   JOURNAL OF LIPID RESEARCH

The LDL Receptor

(2009) Joseph L. Goldstein et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression

(2009) Patrick Labonté et al.   HEPATOLOGY

Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment

(2008) G. Lambert et al.   CLINICAL CHEMISTRY

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels

(2008) Gaétan Mayer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Functional analysis of sites within PCSK9 responsible for hypercholesterolemia

(2008) Shilpa Pandit et al.   JOURNAL OF LIPID RESEARCH

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population

(2007) Yasuko Miyake et al.   ATHEROSCLEROSIS